相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
Bruna Cerbelli et al.
VIRCHOWS ARCHIV (2020)
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Alessio Cortellini et al.
EUROPEAN JOURNAL OF CANCER (2020)
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini et al.
ONCOLOGIST (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine
Anna Passarelli et al.
TUMOR BIOLOGY (2019)
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
Mehmet Asim Bilen et al.
BMC CANCER (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer
M. Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J. Martini et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios
Rebecca Tay et al.
JOURNAL OF THORACIC DISEASE (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Description of CD8(+) Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer
Martha R. Vieyra-Lobato et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Frederike Bensch et al.
NATURE MEDICINE (2018)
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
Andrea Botticelli et al.
ONCOTARGET (2017)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Silvana Morello et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli et al.
ONCOTARGET (2017)
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh et al.
CANCER IMMUNOLOGY RESEARCH (2017)
History and current state of immunotherapy in glioma and brain metastasis
Tresa McGranahan et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Targeting the programmed cell death-1 pathway in breast and ovarian cancer
Leisha A. Emens et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
Cuihua Wang et al.
MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The prognostic significance of PD-L1 in bladder cancer
Yide Huang et al.
ONCOLOGY REPORTS (2015)
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
Ninh M. La-Beck et al.
PHARMACOTHERAPY (2015)
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
David McDermott et al.
CANCER TREATMENT REVIEWS (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu et al.
MEDICAL ONCOLOGY (2011)
Osteoimmunology and the effects of the immune system on bone
Hiroshi Takayanagi
NATURE REVIEWS RHEUMATOLOGY (2009)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
